Core Viewpoint - Jia Shitang (002462) is set to resume trading following a share transfer agreement with Tongrentang Group, marking a significant change in its controlling shareholder and actual controller [1][2]. Group 1: Share Transfer Agreement - On February 2, Jia Shitang announced that its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Tongrentang Group, transferring approximately 41.18 million shares and 41.87 million shares respectively [1]. - After the completion of this transaction, Tongrentang Group will become the controlling shareholder, and the actual controller will change to the State-owned Assets Supervision and Administration Commission of the Beijing Municipal Government [1]. Group 2: Resumption of Trading - Jia Shitang's stock is scheduled to resume trading on February 4, 2026, at the opening of the market [2]. Group 3: Regulatory Approvals - The share transfer is subject to approval from the relevant state-owned assets supervision authority, antitrust review by the State Administration for Market Regulation, compliance confirmation by the Shenzhen Stock Exchange, and registration with China Securities Depository and Clearing Corporation Limited [5].

Buybacks and Shareholder Actions - Guizhou Moutai has repurchased a total of 416,900 shares, accounting for 0.0333% of its total share capital, with a total payment of 571 million yuan [1] - Contemporary Amperex Technology Co., Ltd. has repurchased 15,990,800 shares, representing 0.3628% of its total A-share capital, with a total transaction amount of 4.386 billion yuan [2] - SF Holding has repurchased 5,095,850 shares, which is 1.01% of its total share capital, with a total amount of approximately 2 billion yuan [10] - Wireless Media has seen its major shareholders reduce their stakes, with Wensheng Fund and its concerted parties reducing 4% of the total share capital [12] Corporate Actions and Financial Updates - Tai Ling Microelectronics announced that its second-largest shareholder, the National Integrated Circuit Industry Investment Fund, has reduced its stake from 6.95% to 5.97% by selling 2,321,300 shares [3] - Nape Mining has terminated its investment in Swiss Veritas Resources AG due to changes in delivery conditions, with no breach of contract [4] - Huangshan Tourism plans to invest approximately 530 million yuan in the construction of a hotel project, with a total building area of 79,178.15 square meters [8][9] - *ST Jinling's restructuring plan has been approved by the court, allowing the company to enter the execution phase of the plan [7] Performance and Sales - Country Garden reported a contract sales amount of approximately 2.21 billion yuan for January 2026, with a sales area of about 280,000 square meters [11] - Industrial Fulian has accumulated a total buyback fund of 247 million yuan as of January 31, 2026 [17] - Yutong Bus produced 2,167 vehicles in January 2026, a decrease of 15.35% year-on-year [17]

Group 1 - The core point of the article is that Jiatang (002462.SZ) announced a share transfer agreement with Tongrentang Group, resulting in a change of controlling shareholder and actual controller to the Beijing Municipal Government State-owned Assets Supervision and Administration Commission [1] Group 2 - The agreement involves the transfer of 41.1808 million shares and 41.8764 million shares from Guangda Industrial and Guangda Health to Tongrentang Group [1] - Following the completion of this transaction, the company's stock will resume trading on February 4, 2026 [1]

Core Viewpoint - The announcement reveals a significant change in the ownership structure of Jia Shi Tang, with the controlling shareholder transitioning to Tong Ren Tang Group, which is ultimately controlled by the Beijing Municipal Government's State-owned Assets Supervision and Administration Commission [1] Group 1: Share Transfer Details - On February 2, Jia Shi Tang's shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Tong Ren Tang Group, transferring 41.1808 million shares and 41.8764 million shares respectively [1] - Following the completion of this transaction, Tong Ren Tang Group will become the controlling shareholder of Jia Shi Tang [1] Group 2: Regulatory Compliance - Jia Shi Tang has applied to the Shenzhen Stock Exchange for the resumption of trading, which is set to commence on the morning of February 4 [1] - The company is adhering to the relevant regulations outlined in the Shenzhen Stock Exchange's listing rules and self-regulatory guidelines [1]

Core Viewpoint - The transfer of shares from Guangda Health and Guangda Industry to Tongrentang Group marks a significant change in the ownership structure of Jiashitang, with Tongrentang becoming the controlling shareholder [1] Group 1: Share Transfer Details - Guangda Health and Guangda Industry signed a share transfer agreement with Tongrentang Group, transferring a total of 83,057,236 shares, which accounts for 28.48% of the company's total shares [1] - The transfer price is set at RMB 17.59 per share, totaling RMB 1,460,976,781.24 for the entire transaction [1] - Guangda Health will transfer 41,876,431 shares (14.36% of total shares) for RMB 736,606,421.29, while Guangda Industry will transfer 41,180,805 shares (14.12% of total shares) for RMB 724,370,359.95 [1] Group 2: Changes in Control - Following this equity change, Tongrentang Group will become the controlling shareholder of Jiashitang, with the Beijing Municipal State-owned Assets Supervision and Administration Commission (Beijing SASAC) becoming the actual controller of the company [1] - Jiashitang's stock will resume trading on February 4, 2026, at the market opening [1]

证券代码：002462 证券简称：嘉事堂 公告编号：2026-05 嘉事堂药业股份有限公司 关于权益变动的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、2026 年 2 月 2 日，嘉事堂药业股份有限公司（以下简称"嘉事堂""公 司"或"上市公司"）股东中国光大医疗健康产业有限公司（以下简称"光大健 康"或"转让方一"）、中国光大实业（集团）有限责任公司（以下简称"光大 实业"或"转让方二"）与中国北京同仁堂（集团）有限责任公司（以下简称"同 仁堂集团"或"受让方"）签署了《股份转让协议》，光大健康、光大实业拟通 过协议转让方式将其合计持有的公司 83,057,236 股股份（占公司股份总数的 28.48% 1）转让给同仁堂集团。 2、本次权益变动后，同仁堂集团将成为公司控股股东，北京市人民政府国 有资产监督管理委员会（以下简称"北京市国资委"）将成为公司实际控制人。 3、本次交易不触及要约收购，亦不构成关联交易，不会对公司正常生产经 营造成不利影响，不存在损害公司及中小股东利益的情形，亦不存在违反相关承 诺的情形。 4、本次权益 ...

关于筹划控制权变更事项进展暨复牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司股票自 2026 年 2 月 4 日（星期三）开市起复牌。 2、本次控制权变更事项能否最终实施完成及完成时间尚存在不确定性，敬 请广大投资者关注后续公告，注意投资风险。 证券代码：002462 证券简称：嘉事堂 公告编号： 2026-04 嘉事堂药业股份有限公司 停牌期间，相关各方积极推进本次交易各项工作，公司预计无法在 2026 年 1 月 30 日（星期五）上午开市起复牌。经公司向深圳证券交易所申请，公司 股票（证券简称：嘉事堂，证券代码：002462）自 2026 年 1 月 30 日（星期五） 开市起继续停牌，预计停牌时间不超过 3 个交易日。具体内容详见公司于当日 披露的《嘉事堂药业股份有限公司关于筹划控制权变更事项进展暨继续停牌公 告》（公告编号：2026-03）。 二、进展情况说明 2026 年 2 月 2 日，公司股东光大实业、光大健康与中国 ...

Core Viewpoint - The pharmaceutical company Jiasitang (002462.SZ), under the China Everbright Group for eight years, is undergoing a significant ownership change due to a planned share transfer by its major shareholders, which may lead to a change in the controlling shareholder and actual controller [1][2]. Group 1: Ownership Change - Jiasitang announced a stock suspension starting January 28, 2026, due to the planned share transfer by its largest shareholders, China Everbright Industrial Group and its subsidiary, China Everbright Medical Health Industry [2]. - The stock suspension is expected to last no more than two trading days, with the company committed to timely disclosures regarding the matter [2]. Group 2: Business Overview - Jiasitang's core business is pharmaceutical wholesale and distribution, which accounts for over 94% of its total revenue as of the end of 2024 [3]. - The company operates a comprehensive business system covering pharmaceutical wholesale, retail, logistics, and medical device supply chains, and has over 200 directly-operated pharmacies in Beijing [3]. Group 3: Financial Performance - Jiasitang has faced declining financial performance, with net profits decreasing from 297 million yuan in 2022 to 161 million yuan in 2024, marking a 35.75% year-on-year decline in 2024 [5]. - In the first three quarters of 2025, the net profit further declined by 38.81% year-on-year, totaling 141 million yuan [5]. - The company's gross margin has dropped significantly from over 10% to 6.59% in 2023, with a slight recovery to 6.61% in 2024, but falling again to 6.28% in the first three quarters of 2025 [7]. - Revenue has also contracted, with a 20% year-on-year decline to 24.02 billion yuan in 2024 and a 21.80% decline to 14.46 billion yuan in the first three quarters of 2025 [7]. Group 4: Strategic Considerations - The ongoing pressure on performance may lead the controlling shareholders to consider optimizing asset allocation and focusing on core business areas [8].

Core Viewpoint - The pharmaceutical company Jiasitang (002462.SZ), under the China Everbright Group for eight years, is undergoing a significant ownership change due to a planned share transfer by its major shareholders, which may lead to a change in the controlling shareholder and actual controller [2][5]. Group 1: Ownership Change - Jiasitang announced a stock suspension starting January 28, 2026, due to the uncertainty surrounding the potential change in control [2][5]. - The major shareholders, China Everbright Industrial Group and its subsidiary China Everbright Medical Health Industry, hold 14.36% and 14.12% of Jiasitang's shares, respectively [6]. Group 2: Business Overview - Jiasitang focuses on pharmaceutical distribution, with over 94% of its total revenue coming from pharmaceutical wholesale as of the end of 2024 [7]. - The company operates a chain of "Jiasitang" pharmacies, with over 200 directly operated stores in Beijing, previously being one of the largest direct pharmacy operators in the region [8]. Group 3: Financial Performance - Jiasitang's net profit has been declining for three consecutive years, with figures of 297 million yuan, 250 million yuan, and 161 million yuan from 2022 to 2024, marking a significant drop of 35.75% in 2024 [11]. - In the first three quarters of 2025, the net profit further decreased by 38.81% year-on-year, amounting to 141 million yuan [12]. - The company's gross margin has fallen from over 10% to 6.59% in 2023, with a slight recovery to 6.61% in 2024, but dropping again to 6.28% in the first three quarters of 2025 [14]. - Revenue has also contracted, with 2024 revenue at 24.02 billion yuan, down approximately 20%, and 2025 revenue for the first three quarters at 14.46 billion yuan, down 21.80% [15].

Core Viewpoint - The company 嘉事堂 announced a potential change in its controlling shareholder and actual controller due to a planned equity transfer by its shareholder 光大实业, leading to a suspension of its stock trading [1] Group 1: Company Announcement - 嘉事堂 received a written notice from its shareholder 光大实业 regarding the planning of an equity transfer, which may result in a change of the company's controlling shareholder and actual controller [1] - The company has applied for a trading suspension starting from January 28, as the transaction is still in progress and no formal agreement has been signed yet [1] - Due to the uncertainty surrounding the transaction, 嘉事堂 has applied for an extension of the trading suspension, which is expected to last no more than three trading days [1]